EUVIMEDEUVIMED entdecken
Open Access

Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus

Jonah Elliff iD, Lindsey Grady, Kyle L O'Donnell, Caitlin Messingham, Kai J Rogers, Jobaida Akther, Andrew Thurman, Rahul Vijay, Alejandro Pezzulo, Troy Randall, Andrea Marzi iD, Noah S Butler iD und 1 weitere

mBio · 2026

DOI: 10.1128/mbio.02796-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2026. Verfasst von Jonah Elliff und 12 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: Ebola Vaccines, Ebolavirus, Hemorrhagic Fever, Ebola, Lymph Nodes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The filovirus, Ebola virus (EBOV), causes outbreaks of EBOV disease (EVD) throughout equatorial Africa. ERVEBO is a replication-competent recombinant vesicular stomatitis virus-vectored vaccine encoding the EBOV glycoprotein (recombinant vesicular stomatitis virus [rVSV]/EBOV), which is licensed to control EVD outbreaks. EVD outbreaks occur in regions endemic for Plasmodium -caused malaria. Plasmodium infections persist due in part to the parasite’s ability to evade sterilizing immunity, which also dampens immune responses to heterologous vaccines. Acute murine Plasmodium infection at the time of rVSV/EBOV vaccination reduced vaccine-mediated protection against mouse-adapted EBOV (ma-EBOV) challenge. Decreased protection was associated with a Plasmodium- induced interferon gamma-mediated decrease of rVSV/EBOV replication in lymph node macrophages, resulting in reduced primary anti-EBOV glycoprotein antibody responses. Higher doses of rVSV/EBOV partially overcame the antibody deficits and elicited protective responses. Evidence of the negative impact of Plasmodium on the efficacy of low-dose rVSV/EBOV vaccine protocols supports the use of high antigen loads in the effective management of EVD outbreaks. IMPORTANCE We show that a blood-stage murine Plasmodium infection negatively impacts the primary antibody response elicited by low-dose recombinant vesicular stomatitis virus (rVSV)/Ebola virus (EBOV) vaccination and results in reduced protection against a lethal dose of mouse-adapted EBOV. This defect occurs within the draining lymph node due to the elevation of interferon gamma elicited in Plasmodium yoelii ( Py) -infected mice. The Py -imposed decrease in vaccine-mediated protection can be overcome with higher doses of rVSV/EBOV. While the strong protection conferred by rVSV/EBOV and significant side effects known to be associated with this vaccine have led to the suggestion that the vaccine dosage be reduced, our studies provide a rationale for maintaining the current higher dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ebola VaccinesEbolavirusHemorrhagic Fever, EbolaLymph NodesMalariaMacrophagesAnimalsMiceAntibodies, ViralVesiculovirusFemaleInterferon-gammaVaccines, Synthetic

Stichwörter der Autor:innen

CD169 macrophagesEbola virusPlasmodiumfilovirusinterferon gammalymph nodevaccine

Substanzen

Ebola VaccinesAntibodies, ViralInterferon-gammaVaccines, Synthetic

Autor:innen und Institutionen

  • Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, Iowa, USA.
  • Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA.
  • Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
  • Department of Medicine, Divisions of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, Alabama, USA.
  • Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.

ORCID-Profile: Jonah Elliff, Andrea Marzi, Noah S Butler, Wendy Maury

Förderung

  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Elliff, J., Grady, L., O'Donnell, K. L., Messingham, C., Rogers, K. J., Akther, J., Thurman, A., Vijay, R., Pezzulo, A., Randall, T., Marzi, A., Butler, N. S., & Maury, W. (2026). Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus. mBio. https://doi.org/10.1128/mbio.02796-25

Vancouver

Elliff J, Grady L, O'Donnell KL, Messingham C, Rogers KJ, Akther J, et al. Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus. mBio. 2026. doi:10.1128/mbio.02796-25

BibTeX
@article{Elliff2026,
  author = {Elliff, Jonah and Grady, Lindsey and O'Donnell, Kyle L and Messingham, Caitlin and Rogers, Kai J and Akther, Jobaida and Thurman, Andrew and Vijay, Rahul and Pezzulo, Alejandro and Randall, Troy and Marzi, Andrea and Butler, Noah S and Maury, Wendy},
  title = {Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus},
  journal = {mBio},
  year = {2026},
  doi = {10.1128/mbio.02796-25}
}
Kostenlos starten →